Mersana Therapeutics Inc Total Liabilities

Latest as of September 2025: $122.22 Million USD

Mersana Therapeutics Inc total liabilities. Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has total liabilities worth $122.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MRSN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Mersana Therapeutics Inc (2015–2024)

Total liabilities of Mersana Therapeutics Inc from 2015 to 2024. This chart illustrates how Mersana Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Mersana Therapeutics Inc (MRSN) long-term investment share to see how much of total assets are deployed in long-term investments.

Mersana Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Mersana Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Rajthanee Hospital Public Company Limited BK:RJH	Thailand	฿1.88 Billion
Cheng Fwa Industrial Ltd TWO:5426	Taiwan	NT$871.70 Million
Fasadgruppen Group AB ST:FG	Sweden	Skr4.36 Billion
PChome Online TWO:8044	Taiwan	NT$23.50 Billion
Hankook Cosmetics Manufacturing Co Ltd KO:003350	Korea	₩117.16 Billion
Gevelot PA:ALGEV	France	€66.68 Million
Ontex Group NV BR:ONTEX	Belgium	€1.21 Billion
Samwha Electri KO:009470	Korea	₩56.67 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Mersana Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Mersana Therapeutics Inc balance sheet assets.

Liquidity & Leverage Metrics

Mersana Therapeutics Inc Total Liabilities Ratios Explained

Mersana Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.39	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.95	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mersana Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mersana Therapeutics Inc (2015–2024)

The table below shows the annual total liabilities of Mersana Therapeutics Inc from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	$154.17 Million	-18.49%
2023-12-31	$189.16 Million	-21.93%
2022-12-31	$242.28 Million	+187.17%
2021-12-31	$84.37 Million	+86.20%
2020-12-31	$45.31 Million	+55.06%
2019-12-31	$29.22 Million	-58.08%
2018-12-31	$69.71 Million	+14.80%
2017-12-31	$60.72 Million	-62.22%
2016-12-31	$160.71 Million	+181.44%
2015-12-31	$57.10 Million	--

About Mersana Therapeutics Inc

NASDAQ:MRSN USA Biotechnology

Market Cap

$145.36 Million

Market Cap Rank

#17566 Global

#4168 in USA

Share Price

$29.08

Change (1 day)

+0.14%

52-Week Range

$8.04 - $29.10

All Time High

$29.10